Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - June 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-06-26 7:00 AM EDT | Phio Pharmaceuticals Corp.
HEALWELL AI Announces Voting Results of 2026 AGSM
Toronto, Ontario--(Newsfile Corp. - June 26, 2026) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "Company"), a healthcare artificial intelligence company focused on preventative care, is pleased to announce the voting results from its annual general and special meeting of the shareholders of the Company held on June 25, 2026 (the "Meeting"). Shareholders representing approximately 66.83% of the votes attributable to HEALWELL's outstanding sha
Technologies, Soins de santé et hôpitaux
2026-06-26 5:42 AM EDT | HEALWELL AI
Resverlogix Announces Voting Results from the 2026 Meeting of Shareholders
Calgary, Alberta--(Newsfile Corp. - June 25, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", or the "Corporation") today held its Annual Meeting of Shareholders (the "Meeting") in Calgary, Alberta. During business proceedings at the Meeting, shareholders elected Five (5) Board members until the next annual meeting. The voting results of shares represented at the Meeting for individual directors were as follows:
Technologies, Biotechnologies, Soins de santé et hôpitaux
2026-06-25 9:12 PM EDT | Resverlogix Corp.
Medexus Announces Fiscal Year 2026 Results, Demonstrating Continued Momentum and Strong Product-Level Performance of GRAFAPEX (treosulfan) for Injection
Ontario and Chicago, Illinois--(Newsfile Corp. - June 25, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's fourth fiscal quarter and fiscal year ended March 31, 2026 (the company's fiscal Q4 2026 and fiscal year 2026). All dollar amounts in this news release are in US dollars unless specified otherwise. Company overview Medexus is currently focused on deliv
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-06-25 6:00 PM EDT | Medexus Pharmaceuticals Inc.
Veritas Association Management Recognized by Association Management Company Institute with Excellence in Client Advancement Award
Chicago, Illinois--(Newsfile Corp. - June 25, 2026) - Veritas Association Management has been selected as the recipient of the 2026 Client Excellence Award from the AMC Institute (AMCI), recognizing the company's outstanding leadership, innovation and commitment to helping an association navigate a period of significant organizational challenge and transformation. The Client Excellence Award honors association management companies that demonstrate exceptional service and measurable impa
2026-06-25 10:47 AM EDT | Veritas Association Management
Envoy Medical Terminates At-the-Market (ATM) Equity Facility
White Bear Lake, Minnesota--(Newsfile Corp. - June 25, 2026) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company pioneering fully implanted hearing solutions, today announced that it has formally terminated its at-the-market equity facility (the "ATM Facility"). The ATM Facility, under which the Company was previously authorized to offer and sell up to $15 million worth of shares of its com
Biotechnologies, Soins de santé et hôpitaux
2026-06-25 8:30 AM EDT | Envoy Medical, Inc.
Phio Pharmaceuticals Announces "How siRNA Therapy can Change the Course of Cancer Treatment" in a Fireside Chat with Force Family Office on Monday, June 29, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - June 25, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will participate in a fireside chat with Harvey Briggs, Chief Communications Officer, Force Family Office. Joining the
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-06-25 7:00 AM EDT | Phio Pharmaceuticals Corp.
Illumisoft Appoints Former White House Chief Healthcare Economist Jonathan Ketcham as Strategic Advisor
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2026) - Illumisoft Lighting Corp. (TSXV: UVC) ("Illumisoft" or the "Company") today announced the appointment of Jonathan Ketcham as a strategic advisor to the Company. Dr. Ketcham brings deep expertise in healthcare economics, public policy, reimbursement, procurement, and technology adoption. His guidance is expected to benefit Illumisoft greatly as it advances its ultraviolet germicidal technology platform toward commercializati
Technologies, Biotechnologies, Soins de santé et hôpitaux, Produits ménagers / de consommation / cosmétiques
2026-06-25 7:00 AM EDT | Illumisoft Lighting Corporation
Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762
King of Prussia, Pennsylvania--(Newsfile Corp. - June 24, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company focused on developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer, today
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-06-24 7:00 AM EDT | Phio Pharmaceuticals Corp.
BioMark Diagnostics Secures Landmark Canadian and European Patent Allowances for Early-Stage Lung Cancer Blood Test
Vancouver, British Columbia--(Newsfile Corp. - June 23, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy technologies focused on the early detection of lung cancer through metabolomics, today announced a major operational milestone that underscores the strength of Canadian life sciences innovation. Coinciding with the global spotlight on Canadian medical innovation taking the stage at the BIO Int
Technologies, Biotechnologies, Soins de santé et hôpitaux
2026-06-23 8:30 AM EDT | BioMark Diagnostics, Inc.
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2026 Financial Results on June 30, 2026
Northvale, New Jersey--(Newsfile Corp. - June 23, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that it will release its 2026 year-end financial results on Monday, June 29, 2026. Elite's management will host a live conference call on Tuesday, June 30th, at 11:30 AM EDT to discuss the company's financial and operating results and provide a general business update. St
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-06-23 7:00 AM EDT | Elite Pharmaceuticals, Inc.
Richards Group Inc. Announces June 2026 Dividend
Toronto, Ontario--(Newsfile Corp. - June 19, 2026) - Richards Group Inc. (TSX: RIC) (the "Company") announced today its cash dividend for the month ended June 30, 2026 of Cdn$0.11 per share. This dividend will be to shareholders of record at the close of business on June 30, 2026 and will be payable on July 14, 2026. Shareholders who are non-residents of Canada may be required to pay all withholding taxes payable in respect of any dividends of income by the Company, whether such dividends a
Soins de santé et hôpitaux, Produits ménagers / de consommation / cosmétiques, Pharmaceutique
2026-06-19 11:14 AM EDT | Richards Group Inc.
Veritas Association Management Expands Strategic Planning Services for Healthcare Associations
Chicago, Illinois--(Newsfile Corp. - June 18, 2026) - Veritas Association Management, a leading association management company serving healthcare and medical specialty organizations, has expanded its service offerings to include strategic planning and board facilitation services designed specifically for healthcare associations. The new service helps boards and leadership teams develop actionable strategic roadmaps while navigating the rapidly changing healthcare environment, including
2026-06-18 2:43 PM EDT | Veritas Association Management
Envoy Medical to Present at Investor Conferences on June 25th
White Bear Lake, Minnesota--(Newsfile Corp. - June 18, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that Brent Lucas, CEO of Envoy Medical, will present at the Virtual Life Sciences Investor Forum and the Biotech Webull Webinar Panel on June 25, 2026. Life Sciences Virtual Investor Forum
Biotechnologies, Soins de santé et hôpitaux
2026-06-18 8:30 AM EDT | Envoy Medical, Inc.
Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - June 18, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-06-18 7:00 AM EDT | Phio Pharmaceuticals Corp.
Altus Copper Applies for Partial Revocation of Failure-to-File Cease Trade Order, Announces Proposed Financing and Provides Further Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - June 17, 2026) - Altus Copper Corp. (the "Company") announces that it has applied to the British Columbia Securities Commission (the "BCSC") and the Ontario Securities Commission (the "OSC") for a partial revocation order (the "Partial Revocation Order") of the failure-to-file cease trade order jointly issued by the BCSC and the OSC on December 5, 2023 (the "FFCTO"). The Company further announces a proposed fina
Aliments / boissons, Soins de santé et hôpitaux, Santé
2026-06-17 5:30 PM EDT | Altus Copper Corp.
WELL Health Announces Voting Results for Election of Directors
Vancouver, British Columbia--(Newsfile Corp. - June 17, 2026) - WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) (the "Company" or "WELL"), a digital health company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce that at its annual general and special meeting held June 16, 2026 (the "Meeting"), all of the nominees for election as directors of the Compa
Technologies, Logiciels, Soins de santé et hôpitaux, Santé
2026-06-17 7:00 AM EDT | WELL Health Technologies Corp.
HEALWELL AI Provides Corporate Update: Multi-Province AI Pilot Results Accepted at AMIA Symposium; Alongside Balance Sheet Strengthening with SpaceX Holdings
HEALWELL successfully completed a pilot evaluating its DARWEN™ AI powered SMART Summary™ and SMART Search™ solutions in multiple provinces across Canada. The pilot demonstrated how clinically validated and interoperable AI can reduce chart review burden, improve access to patient information and support more efficient clinical workflows. HEALWELL is exploring opportunities to expand deployment of its SMART products across additional h
Technologies, Soins de santé et hôpitaux
2026-06-17 3:15 AM EDT | HEALWELL AI
Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2026 Conference Call
Ontario and Chicago, Illinois--(Newsfile Corp. - June 16, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Friday, June 26, 2026 to discuss Medexus's results for its fourth fiscal quarter and fiscal year ended March 31, 2026. Medexus expects to file its financial statements and MD&A after markets close on June 25, 2026. To participate in the call, please dial the following numbers:
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-06-16 5:30 PM EDT | Medexus Pharmaceuticals Inc.
Adia Med Improves Quality of Care with Advanced Ultrasound-Guided IV Training
Winter Park, Florida--(Newsfile Corp. - June 16, 2026) - Adia Med, the regenerative medicine and advanced IV therapy division of Adia Nutrition Inc. (OTCQB: ADIA), today announced a major step forward in patient care quality. Renowned physician Dr. Brian Browning, DO, Lead Physician at Adia Med, will personally train the company's Advanced Practice Registered Nurses (APRNs) and Registered Nurses (RNs) in ultrasound-guided intravenous (IV) insertions and administrations using the innovative Bu
Soins de santé et hôpitaux, Santé
2026-06-16 10:55 AM EDT | Adia Nutrition Inc.